LEPIRUDIN (le-pir'u-din) Refludan Classifications: blood formers, coagulators, and anticoagulants; direct thrombin inhibitor; anticoagulant Pregnancy Category: B |
50 mg powder for injection
Highly specific direct inhibitor of thrombin. One molecule of lepirudin binds to one molecule of thrombin and thereby blocks the thrombogenic activity of thrombin.
Increases PT/INR and aPTT values in relation to the dose given. Effectiveness is indicated by aPTT ratio in target range of 1.5 to 2.5.
Anticoagulation in patients with heparin-induced thrombocytopenia (HIT).
Hypersensitivity to lepirudin; lactation; pregnancy (category B); intracranial bleeding; patients with increased risk of bleeding (e.g., recent surgery, CVA, advanced kidney impairment). Safety and efficacy in children not established.
Serious liver injury (e.g., cirrhosis); concomitant administration with streptokinase; renal impairment.
Anticoagulation Adult: IV 0.4 mg/kg initial bolus (max: 44 mg) followed by 0.15 mg/kg/h (max: 16.5 mg/h) for 210 d, adjust rate to maintain aPTT of 1.52.5 |
Intravenous PREPARE: Direct: Reconstitute by adding 1 mL of sterile water for injection or NS to the 50-mg vial. To prepare bolus dose, withdraw reconstituted solution into a 10-cc syringe and dilute to 10 mL with sterile water for injection, NS or D5W to yield 5 mg/mL. Continuous: Transfer the contents of two reconstituted vials into 250 or 500 mL of D5W or NS to yield of 0.4 or 0.2 mg/mL, respectively. ADMINISTER: Direct: Give over 1520 sec. Continuous: Give at a rate determined by body weight. |
Assessment & Drug Effects
Patient & Family Education